ATE277906T1 - 4-carboxamino-2-methyl-1,2,3,4- tetrahydrochinoline als cetp inhibitoren - Google Patents
4-carboxamino-2-methyl-1,2,3,4- tetrahydrochinoline als cetp inhibitorenInfo
- Publication number
- ATE277906T1 ATE277906T1 AT99940421T AT99940421T ATE277906T1 AT E277906 T1 ATE277906 T1 AT E277906T1 AT 99940421 T AT99940421 T AT 99940421T AT 99940421 T AT99940421 T AT 99940421T AT E277906 T1 ATE277906 T1 AT E277906T1
- Authority
- AT
- Austria
- Prior art keywords
- tetrahydrochinolines
- carboxamino
- methyl
- cetp inhibitors
- cetp
- Prior art date
Links
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10092998P | 1998-09-17 | 1998-09-17 | |
| PCT/IB1999/001529 WO2000017166A1 (en) | 1998-09-17 | 1999-09-10 | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as cetp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE277906T1 true ATE277906T1 (de) | 2004-10-15 |
Family
ID=22282259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99940421T ATE277906T1 (de) | 1998-09-17 | 1999-09-10 | 4-carboxamino-2-methyl-1,2,3,4- tetrahydrochinoline als cetp inhibitoren |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US6147090A (de) |
| EP (1) | EP1114033B1 (de) |
| JP (1) | JP3655193B2 (de) |
| AR (1) | AR021482A1 (de) |
| AT (1) | ATE277906T1 (de) |
| AU (1) | AU5439899A (de) |
| BR (1) | BR9913842A (de) |
| CA (1) | CA2344556A1 (de) |
| CO (1) | CO5150220A1 (de) |
| DE (1) | DE69920727T2 (de) |
| DK (1) | DK1114033T3 (de) |
| DZ (1) | DZ2889A1 (de) |
| ES (1) | ES2228086T3 (de) |
| GT (1) | GT199900149A (de) |
| HN (1) | HN1999000155A (de) |
| MA (1) | MA26687A1 (de) |
| MY (1) | MY121838A (de) |
| PA (1) | PA8481501A1 (de) |
| PE (1) | PE20001048A1 (de) |
| PT (1) | PT1114033E (de) |
| SI (1) | SI1114033T1 (de) |
| SV (1) | SV1999000149A (de) |
| TN (1) | TNSN99172A1 (de) |
| TW (1) | TWI232859B (de) |
| WO (1) | WO2000017166A1 (de) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9602166D0 (en) * | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| US6558659B2 (en) | 2000-04-10 | 2003-05-06 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
| USRE44578E1 (en) | 2000-04-10 | 2013-11-05 | Teva Pharmaceutical Industries, Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
| US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| EP1911462A3 (de) | 2001-01-26 | 2011-11-30 | Schering Corporation | Zusammensetzungen enthaltend einen Sterolabsorptionshemmer |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| US20060287254A1 (en) * | 2001-01-26 | 2006-12-21 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
| CN100509058C (zh) | 2001-01-26 | 2009-07-08 | 先灵公司 | 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药以及对于血管适应症的治疗 |
| US7417039B2 (en) | 2001-01-26 | 2008-08-26 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
| WO2002078625A2 (en) * | 2001-03-28 | 2002-10-10 | Pharmacia Corporation | Therapeutic combinations for cardiovascular and inflammatory indications |
| SE0101161D0 (sv) * | 2001-03-30 | 2001-03-30 | Astrazeneca Ab | New compounds |
| WO2003000295A2 (en) * | 2001-06-21 | 2003-01-03 | Pfizer Products Inc. | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
| CZ20033456A3 (en) | 2001-06-22 | 2004-07-14 | Pfizer Products Inc. | Pharmaceutical compositions comprising adsorbates of amorphous drug |
| EP1404300B1 (de) * | 2001-06-22 | 2009-09-30 | Pfizer Products Inc. | Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren |
| EP1269994A3 (de) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| US7132415B2 (en) | 2001-09-21 | 2006-11-07 | Schering Corporation | Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors |
| WO2003053359A2 (en) | 2001-12-19 | 2003-07-03 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders |
| RU2004121898A (ru) * | 2001-12-19 | 2006-01-20 | Атеродженикс, Инк. (Us) | Производные халкона и их применение для лечения заболеваний |
| EP1469832B2 (de) * | 2002-02-01 | 2016-10-26 | Bend Research, Inc. | Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien |
| AR038375A1 (es) | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
| KR20040083493A (ko) * | 2002-02-01 | 2004-10-02 | 화이자 프로덕츠 인크. | 콜레스테릴 에스테르 전달 단백질 억제제의 제어 방출형제약상 제형 |
| US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| AU2003261826B2 (en) | 2002-08-30 | 2006-02-02 | Japan Tobacco Inc. | Dibenzylamine compound and medicinal use thereof |
| US20090181966A1 (en) * | 2002-10-04 | 2009-07-16 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| EP1556047A4 (de) * | 2002-10-04 | 2009-09-30 | Millennium Pharm Inc | Pgd2-rezeptor-antagonisten zur behandlungvon entz ndlichen erkrankungen |
| EP1556356B1 (de) * | 2002-10-21 | 2006-05-31 | Warner-Lambert Company LLC | Tetrahydrochinolin-derivate als crth2 antagonisten |
| CA2504878A1 (en) | 2002-11-06 | 2004-05-27 | Schering Corporation | Cholesterol absorption inhibitors for the treatment of demyelination |
| AU2003303239A1 (en) * | 2002-12-19 | 2004-07-14 | Atherogenics, Inc. | Process of making chalcone derivatives |
| US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
| ATE461700T1 (de) | 2002-12-20 | 2010-04-15 | Pfizer Prod Inc | Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer |
| JP5137228B2 (ja) | 2003-03-07 | 2013-02-06 | メルク・シャープ・アンド・ドーム・コーポレーション | 高コレステロール血症の処置のための置換アゼチジノン化合物、置換アゼチジノン処方物およびそれらの使用 |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| MXPA05009501A (es) | 2003-03-07 | 2005-10-18 | Schering Corp | Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
| JP2006519869A (ja) | 2003-03-07 | 2006-08-31 | シェーリング コーポレイション | 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用 |
| US20040225018A1 (en) * | 2003-03-17 | 2004-11-11 | Japan Tobacco Inc. | Pharmaceutical compositions of CETP inhibitors |
| CA2519458A1 (en) * | 2003-03-17 | 2004-09-30 | Japan Tobacco Inc. | Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate |
| US20040204450A1 (en) * | 2003-03-28 | 2004-10-14 | Pfizer Inc | Quinoline and quinoxaline compounds |
| TWI494102B (zh) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| AU2004242777B2 (en) * | 2003-05-30 | 2011-05-12 | Ranbaxy Laboratories Limited | Substituted pyrrole derivatives and their use as HMG-Co inhibitors |
| CL2004001884A1 (es) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
| JP2007501218A (ja) | 2003-08-04 | 2007-01-25 | ファイザー・プロダクツ・インク | 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物 |
| US7317025B2 (en) | 2003-09-24 | 2008-01-08 | Johnson & Johnson Pharmaceutical Research & Development, Llc | Non-peptidic NPY Y2 receptor inhibitors |
| CA2554982A1 (en) | 2003-09-26 | 2005-04-07 | Japan Tobacco Inc. | Method of inhibiting remnant lipoprotein production |
| KR20060085675A (ko) * | 2003-10-08 | 2006-07-27 | 일라이 릴리 앤드 캄파니 | 이상지혈증 치료를 위한 화합물 및 방법 |
| EP1918000A2 (de) | 2003-11-05 | 2008-05-07 | Schering Corporation | Verbindungen aus lipidverändernden Wirkstoffen und substituierten Azetidinonen und Behandlungen für Gefäßzustände |
| EP1735320B1 (de) | 2004-03-26 | 2009-06-17 | Eli Lilly And Company | Verbindungen und verfahren zur behandlung von dyslipidämie |
| TWI345568B (en) | 2004-04-02 | 2011-07-21 | Mitsubishi Tanabe Pharma Corp | Tetrahydronaphthyridine derivatives and a process for preparing the same |
| UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| US20060063828A1 (en) * | 2004-06-28 | 2006-03-23 | Weingarten M D | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof |
| MX2007003732A (es) * | 2004-09-29 | 2007-04-23 | Schering Corp | Combinaciones de azetidononas sustituidas y antagonistas de receptor de canabinoide 1. |
| AR054998A1 (es) | 2004-12-03 | 2007-08-01 | Schering Corp | Piperazinas sustituidas como antagonistas de cb1, composicion farmaceutica y uso del compuesto para la manufactura de medicamentos |
| US7700774B2 (en) * | 2004-12-20 | 2010-04-20 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds and their pharmaceutical compositions |
| EP1844078B1 (de) | 2005-02-03 | 2016-09-28 | Bend Research, Inc | Pharmazeutische zusammensetzungen mit erhöhter leistung |
| GT200600093A (es) | 2005-02-24 | 2006-10-19 | Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias | |
| WO2006098394A1 (ja) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | 脂質吸収抑制方法および脂質吸収抑制剤 |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| JP4681526B2 (ja) * | 2005-09-29 | 2011-05-11 | 田辺三菱製薬株式会社 | 医薬組成物 |
| KR101329112B1 (ko) | 2005-11-08 | 2013-11-14 | 랜박시 래보러터리스 리미티드 | (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법 |
| US7897601B2 (en) | 2006-01-18 | 2011-03-01 | Intervet, Inc. | Cannabinoid receptor modulators |
| UY30118A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compueto amina trisustituido |
| UY30117A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
| BRPI0707561A2 (pt) | 2006-02-07 | 2011-05-10 | Hoffmann La Roche | derivados de benzamida e de heteroareno |
| CL2007000667A1 (es) * | 2006-03-14 | 2008-03-14 | Ranbaxi Lab Ltd | Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e |
| WO2007107843A1 (en) * | 2006-03-22 | 2007-09-27 | Pfizer Products Inc. | Methods of treatment with cetp inhibitors |
| UY30244A1 (es) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | Un proceso para preparar derivados de tetrahidroquinolina |
| AU2007274724B2 (en) * | 2006-07-14 | 2012-07-26 | Ranbaxy Laboratories Limited | Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof |
| US7750019B2 (en) | 2006-08-11 | 2010-07-06 | Kowa Company, Ltd. | Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same |
| US7790737B2 (en) | 2007-03-13 | 2010-09-07 | Kowa Company, Ltd. | Substituted pyrimidine compounds and their utility as CETP inhibitors |
| WO2008129951A1 (ja) | 2007-04-13 | 2008-10-30 | Kowa Company, Ltd. | 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬 |
| US20100197564A1 (en) * | 2007-04-19 | 2010-08-05 | Schering Corporation | Diaryl morpholines as cb1 modulators |
| CA2694264A1 (en) * | 2007-06-28 | 2009-01-08 | Intervet International B.V. | Substituted piperazines as cb1 antagonists |
| EP2170846A2 (de) | 2007-06-28 | 2010-04-07 | Intervet International BV | Substituierte piperazine als cb1-antagonisten |
| EP2217596B8 (de) | 2007-10-22 | 2013-11-20 | Merck Sharp & Dohme Corp. | Bicyclische heterocyclische derivate und ihre verwendung als modulatoren der aktivität von gpr 119 |
| CA2724426A1 (en) | 2008-05-19 | 2009-11-26 | Schering Corporation | Bicyclic heterocycle derivatives and use thereof as gpr119 modulators |
| US8822480B2 (en) | 2008-07-16 | 2014-09-02 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and use thereof as GPR119 modulators |
| EP2379547A1 (de) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidinderivate und verfahren zu deren anwendung |
| EP2379562A1 (de) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclische pyranonderivate als agonisten am nicotinsäurerezeptor |
| CA2747809A1 (en) | 2008-12-23 | 2010-07-01 | Joel M. Harris | Bicyclic heterocycle derivatives and methods of use thereof |
| WO2010075273A1 (en) | 2008-12-23 | 2010-07-01 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
| CA2747807A1 (en) | 2008-12-23 | 2010-07-01 | Bernard R. Neustadt | Pyrimidine derivatives and methods of use thereof |
| US8580807B2 (en) | 2009-04-03 | 2013-11-12 | Merck Sharp & Dohme Corp. | Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders |
| AR076024A1 (es) | 2009-04-03 | 2011-05-11 | Schering Corp | Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos |
| AU2010313469A1 (en) | 2009-10-29 | 2012-06-07 | Merck Sharp & Dohme Corp. | Bridged Bicyclic Piperidine Derivatives and methods of use thereof |
| EP2504010A4 (de) | 2009-11-23 | 2013-04-17 | Merck Sharp & Dohme | Fusionierte bizyklische pyrimidinderivate und verwendungsverfahren dafür |
| WO2011062889A1 (en) | 2009-11-23 | 2011-05-26 | Schering Corporation | Pyrimidine ether derivatives and methods of use thereof |
| US9301929B2 (en) | 2009-11-24 | 2016-04-05 | Merck Sharp & Dohme Corp. | Substituted biaryl derivatives and methods of use thereof |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| CN107207483B (zh) | 2014-08-29 | 2020-10-30 | Tes制药有限责任公司 | α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂 |
| EP3866802B1 (de) * | 2018-10-17 | 2024-08-21 | Duke University | Chinon-reduktase-2-inhibitoren zur verwendung als neuroprotektiva |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
| US5276168A (en) * | 1990-06-18 | 1994-01-04 | E. R. Squibb & Sons, Inc. | Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents |
| US5401848A (en) * | 1990-11-26 | 1995-03-28 | E. R. Squibb & Sons, Inc. | Indane and quinoline derivatives |
| JPH0676403B2 (ja) * | 1991-01-18 | 1994-09-28 | エスエス製薬株式会社 | 新規なベンゾ［５，６ シクロヘプタ［１，２−ｂ ピリジン誘導体及びこれを含有する抗アレルギー剤 |
| US5288725A (en) * | 1992-10-15 | 1994-02-22 | Merck & Co., Inc. | Pyrroloquinoline Bradykinin antagonist |
| HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
| DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
| US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| US6462091B1 (en) | 1998-12-23 | 2002-10-08 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications |
-
1999
- 1999-09-07 US US09/391,273 patent/US6147090A/en not_active Expired - Fee Related
- 1999-09-08 PA PA19998481501A patent/PA8481501A1/es unknown
- 1999-09-09 HN HN1999000155A patent/HN1999000155A/es unknown
- 1999-09-10 CO CO99057639A patent/CO5150220A1/es unknown
- 1999-09-10 EP EP99940421A patent/EP1114033B1/de not_active Expired - Lifetime
- 1999-09-10 AR ARP990104556A patent/AR021482A1/es active IP Right Grant
- 1999-09-10 SI SI9930672T patent/SI1114033T1/xx unknown
- 1999-09-10 ES ES99940421T patent/ES2228086T3/es not_active Expired - Lifetime
- 1999-09-10 SV SV1999000149A patent/SV1999000149A/es not_active Application Discontinuation
- 1999-09-10 BR BR9913842-5A patent/BR9913842A/pt not_active Application Discontinuation
- 1999-09-10 DK DK99940421T patent/DK1114033T3/da active
- 1999-09-10 GT GT199900149A patent/GT199900149A/es unknown
- 1999-09-10 WO PCT/IB1999/001529 patent/WO2000017166A1/en active IP Right Grant
- 1999-09-10 TW TW088115690A patent/TWI232859B/zh not_active IP Right Cessation
- 1999-09-10 AT AT99940421T patent/ATE277906T1/de not_active IP Right Cessation
- 1999-09-10 AU AU54398/99A patent/AU5439899A/en not_active Abandoned
- 1999-09-10 PE PE1999000923A patent/PE20001048A1/es not_active Application Discontinuation
- 1999-09-10 CA CA002344556A patent/CA2344556A1/en not_active Abandoned
- 1999-09-10 PT PT99940421T patent/PT1114033E/pt unknown
- 1999-09-10 DE DE69920727T patent/DE69920727T2/de not_active Expired - Fee Related
- 1999-09-10 JP JP2000574076A patent/JP3655193B2/ja not_active Expired - Fee Related
- 1999-09-10 MY MYPI99003922A patent/MY121838A/en unknown
- 1999-09-13 MA MA25764A patent/MA26687A1/fr unknown
- 1999-09-13 TN TNTNSN99172A patent/TNSN99172A1/fr unknown
- 1999-09-17 DZ DZ990189A patent/DZ2889A1/xx active
-
2000
- 2000-09-27 US US09/671,400 patent/US6395751B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2344556A1 (en) | 2000-03-30 |
| ES2228086T3 (es) | 2005-04-01 |
| TNSN99172A1 (fr) | 2005-11-10 |
| DK1114033T3 (da) | 2004-12-20 |
| DE69920727T2 (de) | 2006-03-09 |
| PT1114033E (pt) | 2004-12-31 |
| US6147090A (en) | 2000-11-14 |
| EP1114033A1 (de) | 2001-07-11 |
| EP1114033B1 (de) | 2004-09-29 |
| SV1999000149A (es) | 2000-07-06 |
| AU5439899A (en) | 2000-04-10 |
| MY121838A (en) | 2006-02-28 |
| JP3655193B2 (ja) | 2005-06-02 |
| TWI232859B (en) | 2005-05-21 |
| PE20001048A1 (es) | 2000-10-17 |
| GT199900149A (es) | 2001-03-03 |
| PA8481501A1 (es) | 2001-12-14 |
| BR9913842A (pt) | 2001-06-12 |
| US6395751B1 (en) | 2002-05-28 |
| DE69920727D1 (en) | 2004-11-04 |
| WO2000017166A1 (en) | 2000-03-30 |
| SI1114033T1 (en) | 2005-02-28 |
| MA26687A1 (fr) | 2004-12-20 |
| JP2002526477A (ja) | 2002-08-20 |
| CO5150220A1 (es) | 2002-04-29 |
| AR021482A1 (es) | 2002-07-24 |
| DZ2889A1 (fr) | 2003-12-15 |
| HN1999000155A (es) | 2000-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE297898T1 (de) | 4-carboxamino-2-subsitutierte-1,2,3,4- tetrahydrochinoline als cetp inhibitoren | |
| ATE277906T1 (de) | 4-carboxamino-2-methyl-1,2,3,4- tetrahydrochinoline als cetp inhibitoren | |
| ATE268324T1 (de) | 4-amino substituierte -2-subsituierte-1,2,3,4- tetrahydrochinoline als cetp inhibitoren | |
| DE59710982D1 (de) | Cycloalkano-pyridine als CETP-Inhibitoren | |
| ID29241A (id) | Turunan-turunan kinolin teranelasi-1,2 | |
| CU23049A3 (es) | Dihidropirimidinas. | |
| ID28874A (id) | Inhibitor fosfodiesterase 4 turunan ftalazina. | |
| ATE387448T1 (de) | 4,5-pyrazinoxindole als proteinkinasehemmer | |
| ID26909A (id) | Turunan-turunan 1,3,4-oksadiazolon | |
| ATE317396T1 (de) | 14,15-beta-methylen substituierte androgene | |
| ATE234839T1 (de) | 4,5-azolo-oxindole | |
| ID26368A (id) | Turunan-turunan 2 deoksi higromisin | |
| ATE303996T1 (de) | Substituierte acylaminophenyl-uracile | |
| NO980270L (no) | Trekkanordning | |
| DE60017150D1 (de) | 1,4,5,6 -tetrahydropyrimidine-derivative als vitronectin-hemmer | |
| NO981550D0 (no) | Trekkanordning | |
| ES1039413Y (es) | Nueva ficha-deportista. | |
| ES1040631Y (es) | Nuevo cepillo-baqueta. | |
| ES1040173Y (es) | Nuevo bigudi. | |
| ES1040336Y (es) | Lingote mejorado. | |
| ES1041021Y (es) | Antifaz magnetico. | |
| ES1040589Y (es) | Expositor-dispensador. | |
| ES1040633Y (es) | Escalifono. | |
| ES1039730Y (es) | Rodapie. | |
| ES1042117Y (es) | Mesa-sombrilla. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1114033 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |